The End Of Knowledge - Vault 3 - G.TEC BCI & Neurotechnology Spring School 2024 - Day 8

graph LR classDef stroke fill:#f9d4d4, font-weight:bold, font-size:14px; classDef ms fill:#d4f9d4, font-weight:bold, font-size:14px; classDef franchise fill:#d4d4f9, font-weight:bold, font-size:14px; classDef general fill:#f9f9d4, font-weight:bold, font-size:14px; A[Christoph Guger] --> B[Stroke recovery: functional stimulation,
movement imagination. 1] B --> C[Worldwide centers: positive
patient outcomes. 2] B --> D[Videos: dramatic hand,
finger improvements. 3] B --> E[Higher accuracies: greater
Fugl-Meyer improvements. 4] B --> F[All impairments: significant
Fugl-Meyer increases. 5] B --> G[Second round: further
hand improvements. 6] B --> H[Regained abilities: driving,
walking, independence. 7] B --> I[Lower limb: leg
electrodes, imagery. 8] I --> J[Gait benefits: speed,
motion, spasticity. 9] I --> K[Superior to robotic
assist devices. 10] B --> L[Combined therapy: gains
in both areas. 11] A --> M[MS benefits: gait, fatigue,
quality of life. 15] M --> N[MS protocol: alternating limbs,
brain hemispheres. 16] M --> O[Wheelchair to walking:
videos demonstrate. 17] M --> P[Endurance, speed doubled:
active, independent. 18] M --> Q[Patient interviews: regained
abilities, improvements. 19] M --> R[Reduced MS fatigue:
unique benefit. 20] A --> S[Franchise expansion: treat
more patients. 12] S --> T[Franchise requirements:
systems, accessibility. 21] S --> U[Efficient monitoring: economical
for clinics. 22] S --> V[Slovenia success: 2500 treatments,
expansion plans. 23] A --> W[Detailed assessments: objectively
quantify progress. 13] A --> X[Aligns with stroke
rehab guidelines. 14] A --> Y[Multidisciplinary teams: effective
for neurological disorders. 24] A --> Z[Cost coverage: partial
insurance reimbursement. 25] A --> AA[Global opportunities: new
centers worldwide. 26] A --> AB[Gender neutral: equally effective. 27] A --> AC[Regulatory navigation: approvals
harmonized in EU. 28] A --> AD[Chronic fatigue potential:
significant reductions. 29] A --> AE[BCI mastery: motivation
enables strong performance. 30] class B,C,D,E,F,G,H,I,J,K,L,X stroke; class M,N,O,P,Q,R ms; class S,T,U,V franchise; class A,W,Y,Z,AA,AB,AC,AD,AE general;

Resume:

1.- Recoverix system helps stroke patients recover motor function through functional electrical stimulation and movement imagination, reducing chronic pain.

2.- Recoverix treatment centers are located in Finland, Germany, Japan and other countries worldwide, showing positive patient outcomes.

3.- Videos demonstrate dramatic improvements in patients' hand and finger movement abilities after Recoverix treatment sessions.

4.- Patients with higher classification accuracies (>80%) during Recoverix training sessions showed greater improvements in Fugl-Meyer assessment scores.

5.- Severely, moderately and mildly impaired stroke patients all showed significant Fugl-Meyer score increases after Recoverix treatment.

6.- Performing a second round of 25 Recoverix sessions further improved patients' hand function on top of initial gains.

7.- Patients report Recoverix allowing them to perform daily activities again like driving, increased walking speed, no longer needing a walking stick.

8.- For lower limb/gait Recoverix treatment, electrodes are placed on the paretic limb and patients imagine moving their leg.

9.- Recoverix lower limb therapy improves walking speed, gait, range of motion, reduces ankle and knee spasticity in stroke patients.

10.- Recoverix gait training is more effective than other technologies like robotic assist devices in increasing stroke patients' walking speed.

11.- Stroke patients receiving both upper and lower limb Recoverix therapy showed gains in both areas after each treatment block.

12.- Recoverix is expanding via a franchise system allowing centers to open in many countries to treat more patients.

13.- Detailed pre and post Recoverix treatment assessments objectively quantify patient progress in areas like Fugl-Meyer scores, walking speed, fatigue, spasticity.

14.- Recoverix treatment guidelines align with recommendations from U.S. and Canadian stroke rehabilitation associations for effective therapies.

15.- Multiple sclerosis patients treated with Recoverix showed significantly improved walking speed, gait, foot movement, balance, fatigue and quality of life.

16.- For MS, Recoverix treats all 4 limbs by alternating leg vs contralateral hand to activate both brain hemispheres over 30 sessions.

17.- Videos show MS patients who were wheelchair-bound walking independently with greater range of motion and less freezing of gait after Recoverix.

18.- 6-minute walking endurance and 25-foot walking speed doubled in MS patients, allowing them to be more active and independent after Recoverix.

19.- MS patient interviews highlight regained abilities like lifting foot, improved sleep, driving again, standing straighter, better concentration after Recoverix therapy.

20.- Recoverix significantly reduced physical and cognitive fatigue in MS patients, a benefit not provided by other available MS treatments.

21.- To open a Recoverix franchise center, a location with multiple Recoverix systems and treatment rooms with wheelchair access is recommended.

22.- One therapist can monitor multiple patients receiving Recoverix, making it an efficient and economical treatment option for clinics.

23.- Successful Recoverix franchise in Slovenia has already provided 2500 treatments, aiming for 5 locations so patients can easily access therapy.

24.- Multidisciplinary teams including MDs and PTs work together to make Recoverix treatment effective for a range of neurological disorders.

25.- Recoverix therapy costs are often partially reimbursed by health insurance plans in countries like Austria and Slovenia.

26.- Recoverix franchise opportunities exist in many European and worldwide countries, with new centers opening in Asia, Australia, North/South America.

27.- Gender does not influence improvement rates - Recoverix is equally effective for male and female stroke/MS patients.

28.- Navigating differing medical device regulations is required to provide Recoverix in various countries, but approvals are harmonized across the EU.

29.- Recoverix likely helps chronic fatigue because it significantly reduces fatigue as a "side effect" when treating other neurological conditions.

30.- Developer believes "BCI illiteracy" does not exist and that any user can attain strong BCI performance if they are motivated.

Knowledge Vault built byDavid Vivancos 2024